Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYPHISMO: TetMYB Vaccine and BGB-A317 in Advanced Solid Cancers
NCT03287427Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2018
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TetMYB Vaccine in colorectal cancer (CRC) and adenoid cystic carcinoma (ACC), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Incidence of Grade 3 or 4 or greater adverse events and dose-limiting toxicities at 6 weeks. Started Aug 2018; status: completed.
02
Drugs
TetMYB Vaccine
03
Conditions
colorectal cancer (CRC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03287427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287427.